Lab-Grown Liver Tumor Models to Test Cancer Treatments
Builds patient-derived organoids of liver cancer to test treatment response in adults.
Plain-language title generated from the registry record
Registry title: Organoid Models of Hepatocellular Carcinoma
Key facts
- Where
- Roma, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC CEMAD, Largo A. Gemelli, 8Roma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06929845
- Record updated
- 21 September 2026
- Original description
A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.Read full original descriptionShow less
Organoid Models of Hepatocellular Carcinoma to Test Treatment Efficacy, Exploring Correlations With Tumor Microenvironment and Gut-liver-tumor Axis.
A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.
Inclusion: Capacity to express informed consent; Age ≥18 years; Suspected radiological diagnosis of HCC or diagnosis of HCC with indications for surgical resection.
Exclusion: Contraindications to HCC resection surgery; Active viral infection; Contraindications to liver biopsy (ascites, platelets<50,000, INR>1.7); Age < 18 years; Refusal to sign informed consent to participate in the study.